Other drugs already commercially available or in preparation for testing in MS models (160), or stem cell-based treatments proposed for PMD patients (161) might extend to MCT8 deficiency models too. The gene discussed is SLC16A2; the disease is Pelizeaus-Merzbacher spectrum disorder.